Destacados

Cada año, un comité de expertos debe acometer una ardua tarea: de entre todas las publicaciones de ICREA, debe escoger unas cuantas que destaquen del resto. Es todo un reto: a veces los debates se acaloran, y siempre son difíciles, pero acaba saliendo una lista con las mejors publicaciones del año. No se concede ningún premio, y el único reconocimiento adicional es el honor de ser resaltado en la web de ICREA. Cada publicación tiene algo especial, ya sea una solución especialmente elegante, un éxito espectacular en los medios de comunicación o la simple fascinación por una idea del todo nueva. Independientemente de la razón, se trata de los mejores de los mejores y, como tales, nos complace compartirlos aquí.

LIST OF SCIENTIFIC HIGHLIGHTS

Format: yyyy
  • Higgs Hunting at the LHC (2011)

    Juste, Aurelio (IFAE)
    Martínez Pérez, Mario (IFAE)

    view details
    CLOSE

    Higgs Hunting at the LHC

    Since 2009, the Large Hadron Collider (LHC) at CERN (Geneva, Switzerland) collides protons at a center-of-mass energy of 7 TeV, the highest energy ever reached by a particle accelerator. One of the main goals of the LHC is the search for the Higgs boson, the last piece of the Standard Model that remains undiscovered. The so-called Higgs mechanism was introduced in 1964 to explain the breaking of the electroweak symmetry, leading to a massless photon, mediator of the electromagnetic force, and very heavy W and Z bosons, mediators of the weak interaction. The Higgs mechanism would also explain the mass of fermions as the Higgs field permeates the Universe and interacts with all particles endowing them with their mass. Finally, the existence of a Higgs boson associated with the Higgs field is postulated, although its mass is not predicted and must be determined experimentally. During the last four decades, particle physicists have searched for the Higgs boson. In the 90's, the LEP electron-positron collider at CERN concluded that the Higgs boson, if it exists, should have a mass larger than 114.4 GeV at 95% confidence level (C.L). Since 2002, the quest for the Higgs boson was mainly undertaken by the CDF and D0 experiments at the 1.96 TeV proton-antiproton Tevatron collider at Fermilab (near Chicago, USA). The experiments were able to extend the excluded mass range at 95% C.L. to 156-177 GeV, still leaving much room for the Higgs boson to hide. The analysis of the data delivered in 2011 by the LHC to the ATLAS and CMS experiments has translated into a huge step forward in the quest for the Higgs boson. In particular, the combination of searches at the ATLAS experiment has excluded at 95% C.L. the presence of a Higgs boson with mass in the ranges: 112.7-115.5 GeV, 131-237 GeV, and 251-453 GeV [1-4]. Most importantly, the experiment observes a suggestive excess of events around 126 GeV (see Fig 1) which would be consistent with the potential signal of a Higgs boson, although the observation is not yet statistically significant. It corresponds to a 3.6 standard deviation from the background-only hypothesis (see Fig 2) but, after including look-elsewhere effects,.. 

  • Why might a mutation kill one individual, but not another? (2011)

    Lehner, Ben (CRG)

    view details
    CLOSE

    Why might a mutation kill one individual, but not another?

    Many people have `disease causing' mutations in their genomes but never actually develop a disease. Researchers from the Centre for Genomic Regulation (CRG) have studied how non-genetic variation in gene expression may help to predict whether an individual develops a disease or not.

    The effects of a particular disease causing mutation can be very severe in some individuals, only mild in others, and of no consequence in a lucky few. These differences in the outcome of mutations are usually ascribed to interactions with additional variation (i.e. to genetics) or to interactions with lifestyle, diet etc (i.e. to the environment). However it has long been realised by researchers who work with laboratory animals that even in the absence of genetic variation - and even in a highly controlled laboratory environment - the same mutation can kill one individual and yet have no apparent effect in another. What are the causes of this variation in the effects of inherited mutations?

    Researchers at the CRG have studied this question using the microscopic worm, Caenorhabditis elegans, as a model. Due to its simplicity, C. elegans is one of the most widely studied organisms in biology, and was the first animal to have its genome sequenced. Recently three different Nobel Prizes have been awarded for research using C. elegans. The researchers tested the idea that it is 'random' variation in gene expression (the extent to which a particular gene is turned on or off) during the development of the animal that influences the outcome of each mutation. They developed a method to quantify the activity of genes in developing embryos, allowing them to test the consequences of variation in the expression of particular genes. Using this approach they found that 'random' differences in the expression of a gene can sometimes have quite a big effect. Indeed, by quantifying variation in the expression of both a specific and a more general cellular component, it was possible to predict much more accurately what the consequences of a particular inherited mutation would be for a particular individual.

    The work illustrates how, even if we completely understand all of the genes important for a particular human disease, we may never be able to accurately predict what will happen to each person from their genome sequence alone. Rather, to develop personalised and predictive medicine it will also be necessary to consider the varying extent to which genes are turned on or off in each person.

  • Quantum Simulator of Frustrated Antiferromagnetism (2011)

    Lewenstein, Maciej Andrzej (ICFO)

    view details
    CLOSE

    Quantum Simulator of Frustrated Antiferromagnetism

    Together with the experimental group of Klaus Sengstock in Hamburg we have proposed and realized the first quantum simulator (i.e. quantum computer of special purpose) of frustrated antiferromagnetism. Bose Einstein condensate loaded into an anisotropic triangular lattice undergoes various orderings with respect to the phase of the condensate wave function. In the strongly correlated regime the system should exhibit various exotic quantum states, such as a spin liquid state with non-trivial topological order.

  • Higgs Hunting at the LHC (2011)

    Martínez Pérez, Mario (IFAE)

    view details
    CLOSE

    Higgs Hunting at the LHC

    Since 2009, the Large Hadron Collider (LHC) at CERN (Geneva, Switzerland) collides protons at a center-of-mass energy of 7 TeV, the highest energy ever reached by a particle accelerator. One of the main goals of the LHC is the search for the Higgs boson, the last piece of the Standard Model that remains undiscovered. The so-called Higgs mechanism was introduced in 1964 to explain the breaking of the electroweak symmetry, leading to a massless photon, mediator of the electromagnetic force, and very heavy W and Z bosons, mediators of the weak interaction. The Higgs mechanism would also explain the mass of fermions as the Higgs field permeates the Universe and interacts with all particles endowing them with their mass. Finally, the existence of a Higgs boson associated with the Higgs field is postulated, although its mass is not predicted and must be determined experimentally.

    During the last four decades, particle physicists have searched for the Higgs boson. In the 90's, the LEP electron-positron collider at CERN concluded that the Higgs boson, if it exists, should have a mass larger than 114.4 GeV at 95% confidence level (C.L). Since 2002, the quest for the Higgs boson was mainly undertaken by the CDF and D0 experiments at the 1.96 TeV proton-antiproton Tevatron collider at Fermilab (near Chicago, USA). The experiments were able to extend the excluded mass range at 95% C.L. to 156-177 GeV, still leaving much room for the Higgs boson to hide.

    The analysis of the data delivered in 2011 by the LHC to the ATLAS and CMS experiments has translated into a huge step forward in the quest for the Higgs boson. In particular, the combination of searches at the ATLAS experiment has excluded at 95% C.L. the presence of a Higgs boson with mass in the ranges: 112.7-115.5 GeV, 131-237 GeV, and 251-453 GeV [1-4]. Most importantly, the experiment observes a suggestive excess of events around 126 GeV (see Fig. 1) which would be consistent with the potential signal of a Higgs boson, although the observation is not yet statistically significant. It corresponds to a 3.6 standard deviation from the background-only hypothesis (see Fig. 2) but, after including look-elsewhere effects, it translates into a 1% probability to be a simple background fluctuation.
    In 2012 the LHC experiments will collect much more data, which should allow them to either discover the Higgs boson or completely exclude its existence. A. Juste and M. Martínez lead the analysis effort of the ATLAS data at IFAE, playing a central role in those channels whe

  • New clues into AIDS pathogenesis: the case of genes similarly regulated after retroviral infection in human and nonhuman primates (2011)

    Martínez-Picado, Javier (IrsiCaixa)

    view details
    CLOSE

    New clues into AIDS pathogenesis: the case of genes similarly regulated after retroviral infection in human and nonhuman primates

    High levels of Human Immunodeficiency Virus (HIV-1) replication during the chronic phase of infection usually correlate with rapid progression to severe immunodeficiency. However, a minority of highly viremic individuals remains asymptomatic and maintains high CD4+ T lymphocytes. This tolerant profile is poorly understood and reminiscent of the widely studied nonprogressive disease model of Simian Immunodeficiency Virus (SIV) infection in natural hosts. In a study co-led by researchers at the University of Lausanne and the AIDS Research Institute -IrsiCaixa-, we identified transcriptome differences between rapid progressors and viremic nonprogressors and highlight several genes relevant for the understanding of HIV-1-induced immunosuppression. Rapid progressors were characterized by a specific transcriptome profile of CD4+ and CD8+ T cells similar to that observed in pathogenic SIV-infected rhesus macaques. In contrast, viremic nonprogressors exhibited lower expression of interferon-stimulated genes and shared a common gene regulation profile with nonpathogenic SIV-infected sooty mangabeys. A short list of genes associated with viremic nonprogressors, including CASP1, CD38, LAG3, TNFSF13B, SOCS1, and EEF1D, showed significant correlation with time to disease progression when evaluated in an independent set of CD4+ T cell expression data. This work characterizes 2 minimally studied clinical patterns of progression to AIDS, whose analysis may inform our understanding of HIV pathogenesis. The study is presently exploring the phenotypic traits that differentiate HIV-1/AIDS disease in extended cohorts of rapid progressors (approx. 8% of all HIV-1 infected individuals) and viremic nonprogressors (approx. 0.1% of all HIV-1 infected individuals).

  • A new mechanism of gene expression reprogramming in cancer (2011)

    Méndez de la Iglesia, Raúl (IRB Barcelona)

    view details
    CLOSE

    A new mechanism of gene expression reprogramming in cancer

    Proteins are the ultimate mediators of cellular functions in physiological and pathological conditions. However, much more efforts have been dedicated to study tumor-associated changes in transcription rather than in translation (protein synthesis). In collaboration with Pilar Navarro (IMIM/PRBB) and Paco Real (CNIO), we have found that the RNA-binding protein, and translational regulator, CPEB4 is up regulated in pancreatic ductal adenocarcinomas (PDAs), unveiling a new role for tumor-specific expression of factors that promote tumor growth and vascularization. CPEB4 controls the translation a wide spectra of mRNAs whose translation is reprogrammed in tumors, compared with normal tissues. Among these, a key mRNA encodes for the protease tPA (tissue plasminogen activator). tPA mRNA is stored as a deadenylated repressed mRNA in normal pancreas but becomes cytoplasmically polyadenylated, and translationally activated, in PDAs. Depletion of CPEB4, in vivo and in vitro, prevents tPA expression, malignant transformation of tumoral cells, and tumoral growth, invisibility and vascularization. Preliminary data suggest that the relevance of these findings goes beyond pancreatic cancer. CPEB4 plays a similar role in glioblastoma and the public databases contain information indicating that it is overexpressed in a wide variety of human tumors. Altogether this finding opens a new window of opportunity to generate tools with diagnostic and even therapeutical potential.

    * in collaboration with Eduardo Eyras (ICREA at UPF)